会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS
    • 有机化合物的改进或与有机化合物有关的改进
    • WO2009027626A3
    • 2009-12-10
    • PCT/GB2008002738
    • 2008-08-12
    • SYNGENTA LTDBELL GORDON ALASTAIRHARRIS CLAIR LOUISETOVEY IAN DAVID
    • BELL GORDON ALASTAIRHARRIS CLAIR LOUISETOVEY IAN DAVID
    • A01N25/02
    • A01N25/02A01N37/36A01N37/42A01N43/90A01N2300/00
    • A composition comprising a compound of formula I CH3CH(OH)CC=O)NR1R2 (I) where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl; and at least one agrochemical selected from the group consisting of Trinexepac ethyl, Mandipropamid, Abamectin and Emamectin, with the proviso that the agrochemical is not abamectin or emamectin when the solvent is N-(B-hydroxyethyl)- lactamide. Such compositions may be, or may be comprised by, emulsion concentrates.
    • 包含式I化合物的组合物,其中R 1和R 2各自独立地为氢; 或C 1-6烷基,C 2-6烯基或C 3-6环烷基,其各自任选被至多三个独立选自苯基,羟基,C 1-5烷氧基,吗啉基和NR 3 R 4的取代基取代,其中R 3和R 4各自独立地为C 1 -3烷基; 或苯基,其任选被至多三个独立地选自C 1-3烷基的取代基取代; 或者R 1和R 2与它们所连接的氮原子一起形成吗啉基,吡咯烷基,哌啶基或氮杂环庚烷基环,其各自任选被至多三个取代基取代,所述取代基独立地选自C 1-3烷基; 和至少一种选自由Trinexepac乙基,Mandipropamid,阿维菌素和Emamectin组成的组的农业化学品,条件是当溶剂为N-(B-羟乙基) - 乳酰胺时农药不是阿维菌素或emamectin。 这种组合物可以是或可以由乳液浓缩物构成。
    • 2. 发明申请
    • IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS
    • 有机化合物的改善或有关
    • WO2009027624A3
    • 2009-12-10
    • PCT/GB2008002730
    • 2008-08-13
    • SYNGENTA LTDBELL GORDON ALASTAIRHARRIS CLAIR LOUISETOVEY IAN DAVID
    • BELL GORDON ALASTAIRHARRIS CLAIR LOUISETOVEY IAN DAVID
    • A01N25/02
    • A01N25/02A01N35/10A01N37/34A01N39/02A01N43/36A01N43/54A01N43/56A01N43/653A01N43/70A01N43/90A01N45/02A01N47/30A01N51/00A01N2300/00
    • A composition comprising a compound of formula (I) CH3CH(OH)C(=O)NR1R2 where R1 and R2 are each independently hydrogen; or C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C1-5 alkoxy, morpholinyl and NR3R4 where R3 and R4 are each independently C1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C1-3 alkyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C1-3 alkyl; and at least one biologically active compound, which comprises at least one aromatic five and/or six tnembered ring wherein the ring contains at least one nitrogen as a ring member, with the provisos (i) that the composition does not contain cyproconazole when the compound of formula (1) is selected from the group consisting of N-butoxypropyl lactamide; 1-(hydroxyethyl) piperidinyl lactamide; N-methyl-N-propyl lactamide; N-(1-ethylpropyl) lactamide; N,N-dimethyl lactamide; N-1,4-dimethylpentyl lactamide; N-(2-hydroxyethyl)-N-benzyl lactamide; N-Morpholinyl lactamide; N-methyl-N-butyl lactamide; N-Isobutyl lactamide; N-AlIyI lactamide; N-Ethyl lactamide; N-Ethyl-N-(2-hydroxyethyl) lactamide; and N-isopropyl lactamide; and (ii) that the biologically active compound is not nicotinic acid when the compound of formula (1) is diethyl-lactamide. Such compositions may be, or may be comprised by, emulsion concentrates, particularly so in the case that the compound of formula (I) is dimethyl lactamide and the biologically active compound is the fungicide 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid(9-isopropyl-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide shown in Figure 2.
    • 一种组合物,其包含式(I)化合物:CH 3 CH(OH)C(= O)NR 1 R 2,其中R 1和R 2各自独立地为氢; 或C 1-6烷基,C 2-6烯基或C 3-6环烷基,其各自任选被至多三个独立地选自苯基,羟基,C 1-5烷氧基,吗啉基和NR 3 R 4的取代基取代,其中R 3和R 4各自独立地为C 1 -3烷基; 或任选被至多三个独立地选自C 1-3烷基的取代基取代的苯基; 或R 1和R 2与它们所连接的氮原子一起形成吗啉基,吡咯烷基,哌啶基或氮杂环庚烷环,其各自任选被至多三个独立地选自C 1-3烷基的取代基取代; 和至少一种生物活性化合物,其包含至少一个芳族五和/或六个记录环,其中所述环含有至少一个氮作为环成员,条件是(i)当化合物不含有环丙唑啉时 式(1)的化合物选自N-丁氧基丙基乳酰胺; 1-(羟乙基)哌啶基酰胺; N-甲基-N-丙基乳酰胺; N-(1-乙基丙基)乳酰胺; N,N-二甲基乳酰胺; N-1,4-二甲基戊酰基乳酰胺; N-(2-羟乙基)-N-苄基乳酰胺; N-吗啉基乳酰胺; N-甲基-N-丁基乳酰胺; N-异丁基乳酰胺; N-酰胺酰胺; N-乙基乳酰胺; N-乙基-N-(2-羟乙基)乳酰胺; 和N-异丙基乳酰胺; 和(ii)当式(1)的化合物是二乙基 - 乳酰胺时,生物活性化合物不是烟酸。 这样的组合物可以是或可以由乳液浓缩物组成,特别是在式(I)化合物是二甲基乳酰胺并且生物活性化合物是杀真菌剂3-二氟甲基-1-甲基-1H-吡唑-2-基) (9-异丙基-1,2,3,4-四氢-1,4-亚甲基 - 萘-5-基) - 酰胺,如图2所示。
    • 3. 发明申请
    • FORMULATIONS
    • 配方
    • WO2007107745A2
    • 2007-09-27
    • PCT/GB2007000986
    • 2007-03-21
    • SYNGENTA LTDBELL GORDON ALASTAIRTOVEY IAN DAVID
    • BELL GORDON ALASTAIRTOVEY IAN DAVID
    • C07C235/06A01N25/32A01N43/653A61K8/42A61K31/16A61K2800/75A61Q5/02A61Q19/10C07C235/08C07C235/16C07D295/13C07D295/185A01N37/36A01N2300/00
    • This invention relates to the use of lactamide compounds of formula (I): CH 3 CH(OH)C(=O)NR 1 R 2 , where R 1 and R 2 are each independently hydrogen; or C 1-6 alkyl, C 2-6 alkenyl or C 3-6 cycloalkyl, each of which is optionally substituted by up to three substituents independently selected from phenyl, hydroxy, C 1-5 alkoxy, morpholinyl and NR 3 R 4 where R 3 and R 4 are each independently C 1-3 alkyl; or phenyl optionally substituted by up to three substituents independently selected from C 1-3 alkyl; or R 1 and R 2 together with the nitrogen atom to which they are attached form a morpholinyl, pyrrolidinyl, piperidinyl or azepanyl ring, each of which is optionally substituted by up to three substituents independently selected from C 1-3 alkyl, in formulations to reduce the toxicity associated with other formulation components; to the use of certain lactamide compounds as solvents, especially in formulations, particularly in agrochemical formulations and in environmentally friendly formulations; to novel lactamide compounds; and to processes for preparing lactamide compounds.
    • 本发明涉及式(I)的酰胺化合物:CH 3 CH(OH)C(= O)NR 1 R 2 SUP / 其中R 1和R 2各自独立地为氢; 或C 1-6烷基,C 2-6链烯基或C 3-6环烷基,其各自任选被至多三个 独立地选自苯基,羟基,C 1-5烷氧基,吗啉基和NR 3 R 4的取代基,其中R 3 O / >和R 4各自独立地为C 1-3烷基; 或任选被至多三个独立地选自C 1-3烷基的取代基取代的苯基; 或R 1和R 2与它们所连接的氮原子一起形成吗啉基,吡咯烷基,哌啶基或氮杂环环酮环,其各自任选被至多 在制剂中独立地选自C 1-3烷基的三个取代基以降低与其它制剂组分相关的毒性; 使用某些乳酰胺化合物作为溶剂,特别是在制剂中,特别是在农药制剂和环境友好型制剂中; 新型乳酰胺化合物; 以及制备酰胺化合物的方法。
    • 10. 发明申请
    • FORMULATIONS
    • 配方
    • WO2011010082A2
    • 2011-01-27
    • PCT/GB2010001353
    • 2010-07-15
    • SYNGENTA LTDBELL GORDON ALASTAIRSTOCK DAVIDWAILES JEFFREY STEVEN
    • BELL GORDON ALASTAIRSTOCK DAVIDWAILES JEFFREY STEVEN
    • A01N25/02
    • A01N25/02A01N37/18A01N43/40A01N43/54A01N43/653
    • This invention relates to agrochemical compositions comprising a benzamide compound of formula (I) where R1 is fluoro, methoxy or C1-4 alkyl; R2 and R3 are each independently optionally substituted C1-6 alkyl or optionally substituted C2-6 alkenyl; or R3 is hydrogen and R3 is optionally substituted C5-8 alkyl or optionally substituted C4-6 alkenyl or optionally substituted benzyl; or R2 and R3 and the nitrogen atom to which they are both attached together form an optionally substituted 5-, 6- or 7-membered ring, which ring optionally contains at least one further heteroatom selected from O, N and S; to the use of those benzamide compounds as solvents; to certain novel compounds of formula (I); and to a process for preparing those novel compounds.
    • 本发明涉及农药组合物,其包含式(I)的苯甲酰胺化合物,其中R 1是氟,甲氧基或C 1-4烷基; R2和R3各自独立地为任选取代的C 1-6烷基或任选取代的C 2-6烯基; 或R 3为氢,且R 3为任选取代的C 5-8烷基或任选取代的C 4-6烯基或任选取代的苄基; 或R 2和R 3以及它们所连接的氮原子一起形成任选取代的5-,6-或7-元环,该环任选地含有至少一个选自O,N和S的另外的杂原子; 使用那些苯甲酰胺化合物作为溶剂; 某些新的式(I)化合物; 以及制备这些新化合物的方法。